Syner-Med Improves Sales Execution with Veeva OpenData
08 December 2017 - 12:33AM
Business Wire
Veeva delivers the right data and insights for
UK pharmaceutical company to drive tailored interactions with
customers
Veeva Systems today announced that Syner-Med (PP) Ltd., a
fast-growing U.K. pharmaceutical company, is using Veeva OpenData
and Veeva CRM to empower field teams with accurate customer data
and drive smarter engagement with customers. Veeva OpenData and
Veeva CRM are part of Veeva Commercial Cloud, a suite of
applications that Syner-Med is adopting to establish a foundation
for their commercial operations as the company launches more new
products over the next two years.
“Veeva delivers quality customer data, right in CRM, to improve
our sales execution and create more valued interactions with our
customers,” said Dipak Bhatti, managing director of Syner-Med. “We
now have the foundation in place for a consistent commercial
approach and to support our future growth.”
Syner-Med’s previous data sources limited their ability to track
customer activities and placed a heavy administrative burden on
field reps to maintain accurate customer data. Data change requests
could often take weeks, so sales and marketing teams worked from
outdated information and had a fragmented view of customer
engagement across the company.
Veeva brings together complete customer data and multichannel
engagement to help Syner-Med achieve greater commercial
effectiveness. Veeva OpenData keeps data current using a
combination of data science and Veeva data stewards that can make
change requests within two hours versus the industry average of 10
days or more. As a result, field teams have an accurate view of
their customers in Veeva CRM to deliver smarter, more informed
interactions.
“Quality customer data is key to successful commercial execution
and increased sales and marketing efficiency,” said Rebecca Silver,
global vice president of Veeva OpenData. “With accurate data in
Veeva CRM, Syner-Med field and medical teams can drive more
value-based conversations with their customers.”
Veeva OpenData delivers access to approximately 16 million
healthcare professionals (HCPs) and their healthcare organizations
(HCOs) spanning 42 countries. Veeva OpenData can help customers
achieve greater commercial success and improve sales execution and
customer engagement.
Looking ahead, Syner-Med plans to adopt additional Veeva
Commercial Cloud applications, including Veeva Vault PromoMats to
combine creation, review, and distribution of commercial content
with digital asset management; Veeva Align to perform fast,
accurate territory alignments; Veeva CRM Approved Email and Veeva
CRM Engage to extend reach through digital channels such as email,
online meetings, and virtual events; and Veeva CLM to tailor calls
and make sales materials easy to access and share.
Veeva Commercial Cloud is the life sciences industry’s trusted
foundation for intelligent customer engagement. To learn more about
how Veeva Commercial Cloud is helping life sciences companies place
their customers at the center of their commercial strategies, visit
veeva.com/eu/CommercialCloud.
Additional Information For more on Veeva OpenData, visit:
veeva.com/eu/OpenDataConnect with Veeva on LinkedIn:
linkedin.com/company/veeva-systemsFollow @Veeva_EU on Twitter:
twitter.com/veeva_euLike Veeva on Facebook:
facebook.com/veevasystems
About Veeva Systems Veeva Systems Inc. is a leader in
cloud-based software for the global life sciences industry.
Committed to innovation, product excellence, and customer success,
Veeva has more than 600 customers, ranging from the world's largest
pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in
Europe, Asia, and Latin America. For more information, visit
www.veeva.com/eu.
Forward-looking Statements This release contains
forward-looking statements, including the market demand for and
acceptance of Veeva’s products and services, the results from use
of Veeva’s products and services, and general business conditions,
particularly in the life sciences industry. Any forward-looking
statements contained in this press release are based upon Veeva’s
historical performance and its current plans, estimates, and
expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this
press announcement. Subsequent events may cause these expectations
to change, and Veeva disclaims any obligation to update the
forward-looking statements in the future. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially. Additional
risks and uncertainties that could affect Veeva’s financial results
are included under the captions, “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in the company’s filing on Form 10-Q for the period
ended 31 October, 2017. This is available on the company’s website
at veeva.com under the Investors section and on the SEC’s website
at sec.gov. Further information on potential risks that could
affect actual results will be included in other filings Veeva makes
with the SEC from time to time.
###
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171207005613/en/
Veeva Systems Inc.Sue Glanvillesue@catalystcomms.co.uk+44
(0) 7715 817589orCate Bonthuyscate@catalystcomms.co.uk+44 (0) 7746
546773